Skip to content

South San Francisco, CA, November 15, 2021 – FlemingMartin is pleased to announce that Global Blood Therapeutics (NASDAQ: GBT), a biopharmaceutical company committed to helping underserved patient communities by revolutionizing the treatment of severe blood-based conditions, has hired Robert “Bob” Gatmaitan as Head of Global Total Rewards, Analytics & HR Operations.

Bob brings impressive financial, analytical, and technical skills to GBT, along with strong management experience developed over more than 25 years in the compensation, benefits, HR analytics, and HR operations functions. Until mid-2021, Bob served as Head of Total Rewards at MyoKardia, a biotech pioneering a precision medicine approach to serious, neglected, and rare cardiovascular diseases. MyoKardia was acquired by Bristol Myers Squibb (NYSE: BMY) for $13.1 Billion. Before coming to MyoKardia, for over 12 years, Bob created, developed, and strengthened compensation , sales incentive, and equity programs across the globe for Sanofi Pasteur and Sanofi Genzyme (NASDAQ: SNY).

Prior to joining Sanofi, Bob managed compensation programs in the financial services and insurance industries with Lincoln Financial, ACE Group, and Cigna. He also consulted on a range of compensation-related issues, serving multinational corporations with the Hay Group. Bob earned his B.S. in Business Administration (majoring in Finance) from Drexel University in Philadelphia, PA.

Gbt LogoGlobal Blood Therapeutics (GBT) is working to discover, develop, and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease (SCD). GBT’s Oxbryta is the first treatment approved by the FDA to target an underlying cause of SCD.


Fleming Martin Color Logo Medium 72 PpiFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses on the Life Sciences, Technology, and Financial Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.